Literature DB >> 11386773

A comparison of metacarpophalangeal joint silastic arthroplasty with or without crossed intrinsic transfer.

J A Pereira1, H J Belcher.   

Abstract

Forty-three hands in 36 adults undergoing Silastic interposition arthroplasty of the index, middle, ring and little finger metacarpophalangeal joints for rheumatoid arthritis were randomly allocated to undergo replacement with or without crossed intrinsic transfer. The patients were reviewed at a median of 17 (range, 7-50) months after surgery. The demographic characteristics and pre-operative clinical measurements of the two groups were indistinguishable. Both groups showed improvement in ulnar drift and an altered arc, but no change in total range of motion at the metacarpophalangeal joints. Grip strength and pulp to pulp pinch were significantly and comparably improved in both groups. There was no difference in pain scores or perceived function between the treatment groups. It is concluded that crossed intrinsic transfer does not significantly affect the outcome of Silastic interposition arthroplasty of the metacarpophalangeal joints in rheumatoid patients. Copyright 2001 The British Society for Surgery of the Hand.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11386773     DOI: 10.1054/jhsb.2001.0574

Source DB:  PubMed          Journal:  J Hand Surg Br        ISSN: 0266-7681


  3 in total

1.  [Hand and wrist surgery].

Authors:  E Vögelin; P M Villiger
Journal:  Z Rheumatol       Date:  2011-01       Impact factor: 1.372

2.  Insufficient flexion of the metacarpophalangeal joint of the little finger following Swanson silicone arthroplasty for rheumatoid arthritis.

Authors:  Earl R Bogoch; Benjamin G Escott; Maria G P Judd
Journal:  Hand (N Y)       Date:  2007-06-15

3.  Outcomes of silicone arthroplasty for rheumatoid metacarpophalangeal joints stratified by fingers.

Authors:  Kevin C Chung; Sandra V Kotsis; E F Shaw Wilgis; David A Fox; Marian Regan; H Myra Kim; Frank D Burke
Journal:  J Hand Surg Am       Date:  2009-11       Impact factor: 2.230

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.